SCHEMBL4150171

SCHEMBL4150171

O=C(NCCc1ccncc1)c1ccnc2[nH]c(-c3ccco3)nc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 3/20 0.47
ALDH1A1 P00352 3/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
ADORA2A P29274 5/20 0.44
ADORA1 P30542 5/20 0.44
ADORA3 P0DMS8 3/20 0.44
ADORA2B P29275 1/20 0.44
CACNA1B Q00975 4/20 0.43
APBA1 Q02410 4/20 0.43
RAB9A P51151 3/20 0.43
NPC1 O15118 2/20 0.43
HIF1A Q16665 1/20 0.43
NAMPT P43490 1/20 0.43
KDM4E B2RXH2 1/20 0.42
MEN1 O00255 1/20 0.42
USP2 O75604 1/20 0.42
LMNA P02545 1/20 0.42
POLB P06746 1/20 0.42
MAPT P10636 1/20 0.42
THRB P10828 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4157340 0.94 GSK3B (0.50) GSK3BALDH1A1SMN1; SMN2ADORA2AADORA1
SCHEMBL4153424 0.90 NAMPT (0.55) GSK3BALDH1A1SMN1; SMN2ADORA2AADORA1
SCHEMBL4161610 0.88 GSK3B (0.43) GSK3BALDH1A1SMN1; SMN2ADORA2AADORA1
SCHEMBL4152170 0.88 GSK3B (0.47) GSK3BALDH1A1SMN1; SMN2ADORA2AADORA1
SCHEMBL4161472 0.86 GSK3B (0.53) GSK3BALDH1A1SMN1; SMN2ADORA2AADORA1
SCHEMBL4164633 0.85 GSK3B (0.47) GSK3BALDH1A1SMN1; SMN2ADORA2AADORA1
SCHEMBL4959799 0.85 GSK3B (0.42) GSK3BALDH1A1SMN1; SMN2ADORA2AADORA1
SCHEMBL4159223 0.85 GSK3B (0.56) GSK3B
SCHEMBL4152749 0.85 PKM (0.49) GSK3BALDH1A1SMN1; SMN2ADORA2AADORA1
SCHEMBL4148319 0.84 GSK3B (0.58) GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US claimed
EP-1984370-A1 IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Crystalgenomics, Inc. (KR) 2008-10-29 EP claimed
WO-2007083978-A1 IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME CRYSTALGENOMICS, INC. (KR) 2007-07-26 WO claimed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same GSK3B, GSK3A, MAP3K3 GSK3B 1/4885ALDH1A1 4274/4885SMN1; SMN2 3695/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.